Literature DB >> 19181790

Inherited thrombotic thrombocytopenic purpura.

Miriam Galbusera, Marina Noris, Giuseppe Remuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19181790      PMCID： PMC2635388          DOI： 10.3324/haematol.2008.002493

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  26 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

Review 2.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

Authors:  M Furlan; B Lämmle
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

Review 3.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

4.  In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.

Authors:  Roberta Donadelli; Federica Banterla; Miriam Galbusera; Cristina Capoferri; Sara Bucchioni; Sara Gastoldi; Silvia Nosari; Giuseppe Monteferrante; Zaverio M Ruggeri; Elena Bresin; Friedrich Scheiflinger; Edoardo Rossi; Constantino Martinez; Rosanna Coppo; Giuseppe Remuzzi; Marina Noris
Journal:  Thromb Haemost       Date:  2006-10       Impact factor: 5.249

5.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.

Authors:  Silvia Ferrari; Friedrich Scheiflinger; Manfred Rieger; Geert Mudde; Martine Wolf; Paul Coppo; Jean-Pierre Girma; Elie Azoulay; Christian Brun-Buisson; Fadi Fakhouri; Jean-Paul Mira; Eric Oksenhendler; Pascale Poullin; Eric Rondeau; Nicolas Schleinitz; Benoit Schlemmer; Jean-Louis Teboul; Philippe Vanhille; Jean-Paul Vernant; Dominique Meyer; Agnès Veyradier
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.

Authors:  R S Camilleri; H Cohen; I J Mackie; M Scully; R D Starke; J T B Crawley; D A Lane; S J Machin
Journal:  J Thromb Haemost       Date:  2007-11-20       Impact factor: 5.824

8.  Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion.

Authors:  Isabella Garagiola; Carla Valsecchi; Silvia Lavoretano; Hale Oren; Martina Bohm; Flora Peyvandi
Journal:  Haematologica       Date:  2008-10-02       Impact factor: 9.941

9.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Authors:  Roberta Palla; Silvia Lavoretano; Rossana Lombardi; Isabella Garagiola; Mehran Karimi; Abdolreza Afrasiabi; Mani Ramzi; Raimondo De Cristofaro; Flora Peyvandi
Journal:  Haematologica       Date:  2008-12-30       Impact factor: 9.941

10.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.

Authors:  Koichi Kokame; Masanori Matsumoto; Kenji Soejima; Hideo Yagi; Hiromichi Ishizashi; Masahisa Funato; Hiroshi Tamai; Mutsuko Konno; Kei Kamide; Yuhei Kawano; Toshiyuki Miyata; Yoshihiro Fujimura
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205
View more
  6 in total

1.  A STARD-compliant prediction model for diagnosing thrombotic microangiopathies.

Authors:  Pietro Manuel Ferraro; Gianmarco Lombardi; Alessandro Naticchia; Antonio Sturniolo; Cecilia Zuppi; Valerio De Stefano; Patrizia Bonelli; Ruggero Buonocore; Gianfranco Cervellin; Giuseppe Lippi; Giovanni Gambaro
Journal:  J Nephrol       Date:  2018-01-20       Impact factor: 3.902

2.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

3.  Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report.

Authors:  Jian Chen; Jing-Xia Jin; Xiao-Fei Xu; Xuan-Xuan Zhang; Xing-Nong Ye; Jian Huang
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

4.  Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts.

Authors:  Abiola O Oladapo; Diane Ito; Christopher Hibbard; Stephanie E Bean; Robert N Krupnick; Bruce M Ewenstein
Journal:  Patient       Date:  2019-10       Impact factor: 3.883

5.  Thrombotic microangiopathies.

Authors:  Mohamed Radhi; Shannon L Carpenter
Journal:  ISRN Hematol       Date:  2012-07-25

6.  ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.

Authors:  Erica Rurali; Marina Noris; Antonietta Chianca; Roberta Donadelli; Federica Banterla; Miriam Galbusera; Giulia Gherardi; Sara Gastoldi; Aneliya Parvanova; Ilian Iliev; Antonio Bossi; Carolina Haefliger; Roberto Trevisan; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Diabetes       Date:  2013-06-03       Impact factor: 9.461
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.